These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16268491)

  • 1. Distal embolization during angioplasty for acute myocardial infarction: is pharmacological protection enough?
    De Carlo M; Limbruno U; Pistolesi S; Fontanini G; Petronio AS; Balbarini A; De Caterina R
    Thromb Haemost; 2005 Sep; 94(3):680-1. PubMed ID: 16268491
    [No Abstract]   [Full Text] [Related]  

  • 2. Rescue angioplasty after thrombolysis.
    Sharma S; Bhambi B; Nyitray W
    N Engl J Med; 2006 Apr; 354(15):1639-41; author reply 1639-41. PubMed ID: 16615182
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary percutaneous coronary intervention.
    Kapoor R; Kapoor JR
    N Engl J Med; 2008 Jan; 358(4):431; author reply 432-3. PubMed ID: 18216369
    [No Abstract]   [Full Text] [Related]  

  • 4. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
    Gum PA; Lincoff AM
    Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein IIb/IIIa antagonists: an attractive new approach to reperfusion in acute myocardial infarction.
    Gambhir DS
    Indian Heart J; 1999; 51(3):259-60, 309. PubMed ID: 10624062
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists.
    Morel O; Hugel B; Jesel L; Mallat Z; Lanza F; Douchet MP; Zupan M; Chauvin M; Cazenave JP; Tedgui A; Freyssinet JM; Toti F
    J Thromb Haemost; 2004 Jul; 2(7):1118-26. PubMed ID: 15219195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycoprotein inhibitors and fibrinolysis in myocardial infarction.
    Ring BL
    JAMA; 2000 Dec; 284(24):3124-5. PubMed ID: 11135766
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of therapeutic trends in myocardial infarction.
    Milasinovic D; Teischinger L; Luerzer G; Mohl W
    Wien Klin Wochenschr; 2007; 119(11-12 Suppl 1):15-9. PubMed ID: 19618592
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of acute ST-segment elevation myocardial infarction. I. Reperfusion therapy.
    Glancy DL; Breaux DM; Subramaniam PN; Pappas ND
    J La State Med Soc; 2002; 154(4):183-90; quiz 190. PubMed ID: 12236401
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of angioplasty with stenting in acute myocardial infarction.
    Herrmann HC
    N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 16. No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction.
    Chaitman BR; Lim MJ
    J Am Coll Cardiol; 2004 Jul; 44(2):313-5. PubMed ID: 15261924
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
    Ochała A; Smolka G; Wojakowski W; Gabrylewicz B; Garbocz P; Tendera M
    Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 19. [24-hour invasive cardiology duty in Poland. Percutaneous coronary intervention (PCI) in fresh myocardial infarction as a 24 hour procedure. Experiences from the Institute of Cardiology in Krakow].
    Dudek D; Zmudka K; Dubiel J; Tracz W;
    Kardiol Pol; 2003 Jun; 58 Suppl 4():IV25-30. PubMed ID: 20527115
    [No Abstract]   [Full Text] [Related]  

  • 20. Coupling drug and catheter therapy for myocardial infarction.
    Lincoff AM
    JAMA; 2004 Feb; 291(8):1000-2. PubMed ID: 14982917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.